Rising awareness, innovative therapies, and evolving treatment options drive this growth.

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Verified Market Research® a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive report on the, "Mental Health Apps Market Size and ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

If you’ve been diagnosed with major depressive disorder or a form of anxiety, your mental health provider may prescribe the ...

More than 5 million Americans struggle with opioid use disorder, a physical addiction entwined with America’s health crisis, ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...